A Long-term Follow-up Study in Participants Who Received CTX001
Launched by VERTEX PHARMACEUTICALS INCORPORATED · Dec 20, 2019
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants (or his or her legally appointed and authorized representative or guardian) must sign and date informed consent form (ICF) and, where applicable, an assent form
- • Participants must have received CTX001 infusion in a parent study
- Exclusion Criteria:
- • There are no exclusion criteria
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a global biotechnology company dedicated to the innovation and development of transformative therapies for serious diseases, particularly those with significant unmet medical needs. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex specializes in the research and commercialization of treatments for cystic fibrosis and other genetic disorders. Leveraging cutting-edge science and a commitment to patient-centric solutions, Vertex collaborates with healthcare professionals and researchers to advance clinical trials and bring groundbreaking therapies to market, aiming to improve the lives of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Philadelphia, Pennsylvania, United States
Memphis, Tennessee, United States
Vancouver, British Columbia, Canada
Palo Alto, California, United States
Chicago, Illinois, United States
Toronto, , Canada
London, , United Kingdom
Vancouver, , Canada
Tuebingen, , Germany
Nashville, Tennessee, United States
New York, New York, United States
Brussels, , Belgium
Rome, , Italy
London, , United Kingdom
San Antonio, Texas, United States
Toronto, , Canada
Regensburg, , Germany
Tuebingen, , Germany
Charlotte, North Carolina, United States
Dusseldorf, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials